JP2008516610A5 - - Google Patents

Download PDF

Info

Publication number
JP2008516610A5
JP2008516610A5 JP2007537026A JP2007537026A JP2008516610A5 JP 2008516610 A5 JP2008516610 A5 JP 2008516610A5 JP 2007537026 A JP2007537026 A JP 2007537026A JP 2007537026 A JP2007537026 A JP 2007537026A JP 2008516610 A5 JP2008516610 A5 JP 2008516610A5
Authority
JP
Japan
Prior art keywords
hcv
protein
seq
positions
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007537026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516610A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/037499 external-priority patent/WO2006044923A2/en
Publication of JP2008516610A publication Critical patent/JP2008516610A/ja
Publication of JP2008516610A5 publication Critical patent/JP2008516610A5/ja
Pending legal-status Critical Current

Links

JP2007537026A 2004-10-18 2005-10-18 酵母を用いた慢性c型肝炎感染の治療 Pending JP2008516610A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62015804P 2004-10-18 2004-10-18
PCT/US2005/037499 WO2006044923A2 (en) 2004-10-18 2005-10-18 Yeast-based therapeutic for chronic hepatitis c infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011216827A Division JP2012034700A (ja) 2004-10-18 2011-09-30 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2008516610A JP2008516610A (ja) 2008-05-22
JP2008516610A5 true JP2008516610A5 (enExample) 2008-12-04

Family

ID=36203669

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007537026A Pending JP2008516610A (ja) 2004-10-18 2005-10-18 酵母を用いた慢性c型肝炎感染の治療
JP2011216827A Pending JP2012034700A (ja) 2004-10-18 2011-09-30 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法
JP2013162490A Withdrawn JP2014012679A (ja) 2004-10-18 2013-08-05 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011216827A Pending JP2012034700A (ja) 2004-10-18 2011-09-30 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法
JP2013162490A Withdrawn JP2014012679A (ja) 2004-10-18 2013-08-05 酵母を用いた慢性c型肝炎感染の治療用ワクチンおよびその使用方法

Country Status (12)

Country Link
US (5) US7625569B2 (enExample)
EP (2) EP1809773B1 (enExample)
JP (3) JP2008516610A (enExample)
KR (1) KR20070068460A (enExample)
CN (2) CN101437964B (enExample)
AU (1) AU2005295317B2 (enExample)
BR (1) BRPI0516356A (enExample)
CA (1) CA2584562A1 (enExample)
IL (1) IL182609A (enExample)
MX (1) MX2007004662A (enExample)
SG (1) SG156652A1 (enExample)
WO (1) WO2006044923A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン,インコーポレイテッド 動物を癌から守るための治療用組成物
KR20070068460A (ko) * 2004-10-18 2007-06-29 글로브이뮨 만성 c형 간염에 대한 효모계 치료
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
WO2007008780A2 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2645832A1 (en) * 2006-04-25 2007-11-01 Intercell Ag Hcv vaccinations
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
CN101687030B (zh) * 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
WO2008115610A1 (en) * 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US7840668B1 (en) * 2007-05-24 2010-11-23 Avaya Inc. Method and apparatus for managing communication between participants in a virtual environment
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
EP2200638B1 (en) * 2007-10-09 2016-03-16 The University of Melbourne Compositions for the transfection of cells
EP2331125A4 (en) * 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
MX2011005691A (es) * 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
ES2660597T3 (es) * 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US8911722B2 (en) * 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) * 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
EP2651439B1 (en) * 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
EP2720716B1 (en) * 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
WO2013170305A1 (en) * 2012-05-16 2013-11-21 Adelaide Research & Innovation Pty Ltd Cellular vaccine and method of inducing an immune response in a subject
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
CN105073989A (zh) 2013-02-19 2015-11-18 国立大学法人神户大学 免疫原性多肽表层表达双歧杆菌
EP3578200A1 (en) 2013-02-22 2019-12-11 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
EP3113759B1 (en) 2014-03-05 2021-05-12 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
GB201520638D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
CN106749672B (zh) * 2016-11-18 2020-06-30 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
DE102017012109A1 (de) 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN119818663A (zh) * 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
EP3929295A1 (en) * 2020-06-26 2021-12-29 Universitat Pompeu Fabra Artificial rnas for modulating rna fragments

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5523215A (en) * 1985-03-28 1996-06-04 Chiron Corporation Enhanced purification and expression of insoluble recombinant proteins
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
AU7675491A (en) 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
KR0181517B1 (ko) * 1990-07-09 1999-04-01 나까하라 노부유끼 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US6190864B1 (en) 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
WO1992022571A1 (en) 1991-06-13 1992-12-23 Baxter Diagnostics Inc. Immunoassay for non-a non-b hepatitis
GB9203803D0 (en) 1992-02-21 1992-04-08 Wellcome Found A recombinant polypeptide
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) * 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
ES2197170T3 (es) * 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
EP1845108A3 (en) * 1994-07-29 2007-10-24 Innogenetics N.V. Monoclonal antibodies to purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
ES2244965T3 (es) 1994-07-29 2005-12-16 Chiron Corporation Complejos e1/e2 secretados de virus de la hepatitis c obtenidos de polipeptidos e1 y e2 truncados en c-terminal.
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9416671D0 (en) * 1994-08-17 1994-10-12 Biocine Spa Assay
GB9422814D0 (en) 1994-11-11 1995-01-04 Medinnova Sf Chemical method
KR100195833B1 (ko) * 1995-12-07 1999-06-15 윤종용 팩시밀리에서 자체진단 구현방법
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
JP2001522226A (ja) 1997-01-31 2001-11-13 リサーチ コーポレイション テクノロジーズ インコーポレイテッド セミ−同種異系細胞での癌の免疫療法
GB9703406D0 (en) * 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
FR2760367B1 (fr) 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
DE69841015D1 (de) 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US20050037018A1 (en) 2003-06-20 2005-02-17 Innogentics N.V. HCV combination therapy
US7052696B2 (en) 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
US6747135B1 (en) 1998-10-16 2004-06-08 The Board Of Trustees For The Leland Stanford Junior University Fluorescent dye binding peptides
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
ES2411096T3 (es) 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
DE60039715D1 (de) 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
US6986892B1 (en) 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
DE60036881T2 (de) * 1999-11-24 2008-07-10 Novartis Vaccines and Diagnostics, Inc., Emeryville Neues nichtstrukturelles hcv-polypeptid
US20050074465A1 (en) 1999-11-24 2005-04-07 Michael Houghton HCV fusion proteins with modified NS3 domains
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
US20020169125A1 (en) * 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
AR035868A1 (es) 2001-04-24 2004-07-21 Innogenetics Nv Un acido nucleico recombinante que codifica una proteina de un peptido lider de lisozima de ave o equivalente funcional, un vector que lo comprende, una celula huesped, un metodo para producir una proteina de envoltura del hcv o una parte de la misma.
CN1622828A (zh) * 2001-12-18 2005-06-01 基因创新有限公司 用于诊断和治疗用途的纯化的丙型肝炎病毒外被蛋白
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
PL374349A1 (en) * 2002-07-02 2005-10-17 Chiron Corporation Hcv fusion proteins with modified ns3 domains
ES2312806T3 (es) * 2002-09-09 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Ensayo de vhc.
US20040138204A1 (en) * 2002-10-30 2004-07-15 Harrington James Frederick Compositions and methods for pain reduction
AU2003283365A1 (en) * 2002-11-08 2004-06-07 Innogenetics N.V. HCV vaccine compositions comprising E1 and NS3 peptides
GB0226722D0 (en) 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン,インコーポレイテッド 動物を癌から守るための治療用組成物
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US6989892B2 (en) * 2004-03-22 2006-01-24 Fluke Corporation Optical fiber propagation time measurement
KR20070068460A (ko) * 2004-10-18 2007-06-29 글로브이뮨 만성 c형 간염에 대한 효모계 치료
WO2007008780A2 (en) 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
AU2007286754A1 (en) 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
CN101687030B (zh) 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
WO2008115610A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
EP2331125A4 (en) * 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS

Similar Documents

Publication Publication Date Title
Failla et al. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins
Bartenschlager et al. Kinetic and structural analyses of hepatitis C virus polyprotein processing
Leary et al. Sequence and genomic organization of GBV‐C: A novel member of the Flaviviridae associated with human non‐A‐E hepatitis
Mizushima et al. Two hepatitis C virus glycoprotein E2 products with different C termini
Lin et al. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro
Bartenschlager et al. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation
Major et al. The molecular virology of hepatitis C
Grakoui et al. Expression and identification of hepatitis C virus polyprotein cleavage products
Lin et al. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini
Bartenschlager et al. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase
Tautz et al. NS3 serine protease of bovine viral diarrhea virus: characterization of active site residues, NS4A cofactor domain, and protease–cofactor interactions
Ryan et al. Virus-encoded proteinases of the Flaviviridae.
Butkiewicz et al. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity
Hirowatari et al. Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector
US20100278865A1 (en) Production and use of epitope-tagged hepatitis c virus particle
CN102016026B (zh) 含有来自丙型肝炎病毒的嵌合基因的核酸
ES2273934T5 (es) Antígeno del virus de la hepatitis no a, no b, métodos diagnósticos y vacunas.
EP0763114B1 (en) Hepatitis g virus and molecular cloning thereof
Shimotohno Hepatitis C virus as a causative agent of hepatocellular carcinoma
Yen et al. Cellular proteins specifically bind to the 5′-noncoding region of hepatitis C virus RNA
Khudyakov et al. Artificial mosaic protein containing antigenic epitopes of hepatitis E virus
JP3045778B2 (ja) C型肝炎ウイルスプロテアーゼの不溶性凝集物をリフォールディングするための方法
RU2005102484A (ru) Слитые белки hcv c модифицированными доменами ns3
EP1993603B1 (en) Hepatitis c virus non structural fusion protein
Lazdina et al. Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein